Latest news: 28 March 2025. TROG Members who have made significant contributions both to the work of TROG and to advancing radiation medicine clinical trial research more broadly were recognised with our 2025 Research Excellence Awards this month. We congratulate the following winners on their well-deserved awards, which were
Latest news: 27 March 2025 With a theme of inclusivity and innovation, our Annual Scientific Meeting (ASM) brought together researchers, health professionals and consumers from across Australia and New Zealand with the common goal of advancing cancer care through vital research. More than 310 delegates gathered for the TROG
5 March 2025: TRIAL UPDATE We’re excited to have now opened all Australian sites for the TROG 21.07 – SOCRATES HCC study, which is investigating the use of an advanced radiotherapy technique for early stage hepatocellular (HCC) cancer. With the opening of a clinical trial site at St George
4 March 2025: A decade on from the last participant completing treatment, the BIG 3-07/TROG 07.01 – DCIS trial is continuing to deliver valuable results. Led by TROG Cancer Research, the international, randomised phase III study aimed to improve the treatment outcomes of women diagnosed with ductal carcinoma in-situ
9 January 2025: Two important TROG Cancer Research trials investigating liver cancer and brain metastases resulting from other advanced cancers are set to progress to the next level, after successfully gaining a total of $250,000 in grants from the Tour de Cure cancer charity. Tackling hepatocellular cancer The TROG
7 January 2025: TROG Cancer Research is advancing vital cancer research, with the support of a generous $300,000 donation from the GenesisCare Foundation. The donation will support TROG’s work to promote the prevention and control of cancer through cancer research, in line with our objectives, mission and strategic goals
5 December 2024: Study shows huge improvement in progression-free survival with adjuvant rituximab containing therapy. Newly published findings of extended follow-up from a TROG Cancer Research trial of radiotherapy plus chemo-immunotherapy in follicular lymphoma (TROG 99.03 – Follicular lymphoma) provide valuable evidence in support of changing the current standard
28 November 2024: In this Q&A, TROG President A/Prof Puma Sundaresan talks about her passion for patient-centred cancer care, her vision for TROG and future directions for radiation medicine research. Q: What attracted you to the field of radiation oncology, and drives your continued passion for this field? A:
November 2024: Congratulations to the Trek4TROG team for successfully completing our second annual fundraising hike in the Blue Mountains in October. The team of nine adventurous trekkers, including TROG staff and members, took on the challenge of a spectacular one-day hike through the Blue Mountains west of Sydney, to
24 October 2024: Newly published findings from the ICR-CTSU/2014/10049/TROG 14.02 RAIDER trial offer promise for the use of complex adaptive radiotherapy as an alternative to radical surgery for bladder cancer. The RAIDER team published their significant phase II trial findings in the European Urology journal in October. The trial,
For over 30 years, Trans-Tasman Radiation Oncology Group has been dedicated to improving the way radiation medicine is delivered to cancer patients with ongoing scientific research, clinical trials, and cutting-edge technology.
Latest News
Keep up to date with TROG news, subscribe to our community newsletter.
ABN: 45 132 672 292
